25 EyeWorld Asia-Pacific | June 2025 SURGICAL OUTCOMES possible by the system’s use of AI to recognize various eye configurations, drawing on decades of ICL surgery knowledge, and its ability to standardize optimized UBM images through advanced software development. Beyond ICLs, Revai has been amassing a collection of realworld patient-reported outcomes for IOLs. This data is providing information on how different IOLs are functioning in the real world and how well they align with patients’ anatomy and lifestyle, Dr. Zaldivar said. Revai’s data (n=3,600) on premium IOLs has shown that patients with advanced-technology IOLs who experience dysphotopsias do not necessarily undergo true neuroadaptation to these visual disturbances, but rather what Dr. Zaldivar calls “neuro-resignation.” Even though there is a modest improvement in photic symptoms, the glare and halos are still perceived but are accepted more naturally. Night driving disturbance scores were similar at 1 month and 1 year, but overall satisfaction with the IOL improved. Dr. Zaldivar also pointed out data in the system that compared trifocal and EDOF IOLs and noted that the intermediate vision, which is supposed to be stronger with an EDOF, is weaker than intermediate vision with trifocals, at least in patients’ perception. Dr. Zaldivar said data collection from patients is conducted via email at 1 week postop, 1 month, 3 months, 6 months, and 1 year. The questionnaires ask about patient satisfaction with the surgeon, spectacle independence at different distances, level of dysphotopsia, whether their expectations are met, quality of service, confidence in the physician, and other experience-related factors. Dr. Zaldivar is working on building up data sets and applications in Revai for retina, glaucoma, dry eye, cataract, and refractive surgery. “We are learning from the patient in a very standardized and automatized way, and that’s what’s driving improvement in what we’re doing with patient selection— which conditions in the eye are playing an important role that we have to pay more attention to,” Dr. Zaldivar said. Recent advances in software and AI over the past two years have significantly accelerated this process, he continued. This is due to the availability of accurate patient satisfaction data, which can be combined with various aspects of the eye, including aberrometry, pupil size, lens power, and chord mu. By integrating all these variables, we are now able to extract deeper insights and make more informed decisions, he said. About the Physician Roger Zaldivar, MD, MSc, MBA | Instituto Zaldivar, CEO, RevaiCare LLC, Mendoza, Argentina | zaldivar@zaldivar.com Relevant Disclosure Zaldivar: RevaiCare This article originally appeared in the March 2025 issue of EyeWorld. It has been slightly modified and appears here with permission from the ASCRS Ophthalmic Services Corp.
RkJQdWJsaXNoZXIy Njk2NTg0